FDA approval of lecanemab: the real start of widespread amyloid PET use? - the EANM Neuroimaging Committee perspective

Verger, A.; Yakushev, I.; Albert, N.L.; van Berckel, B.; Brendel, M.; Cecchin, D.; Aguiar Fernández, Pablo; Fraioli, F.; Guedj, E.; Morbelli, S.; Tolboom, N.; Traub-Weidinger, T.; Van Weehaeghe, D.; Barthel, H.

Statistics

Statistics

View Usage Statistics

Identifiers

Identifiers

URI: http://hdl.handle.net/20.500.11940/21502

DOI: 10.1007/s00259-023-06177-5

ISSN: 1619-7089

Full record

Services

Services

RIS

Mendeley

Linksolver

Files view or download

Files view or download

Verger A, Yakushev I, Albert NL, van Berckel B, Brendel M, Cecchin D, et al. FDA approval of lecanemab: the real start of widespread amyloid PET use? - the EANM Neuroimaging Committee perspective. Vol. 50, European Journal of Nuclear Medicine and Molecular Imaging. Springer Science and Business Media Deutschland GmbH; 2023. pp. 1553-5. (371.7Kb)

Date issued

2023

Journal title

European Journal of Nuclear Medicine and Molecular Imaging

Type of content

Artigo

MeSH

Humans | Neuroimaging | Positron-Emission Tomography | Amyloid | Alzheimer Disease | Amyloid beta-Peptides

Attribution 4.0 International (CC BY 4.0)

Except where otherwise noted, this item's license is described as Attribution 4.0 International (CC BY 4.0)